Alpine Immune Sciences Inc ALPN presented the first clinical data of povetacicept in autoimmune glomerulonephritis during a late-breaking session at the American Society of Nephrology (ASN) Kidney Week.
In IgAN, treatment with low-dose povetacicept, 80 mg SC every four weeks, was associated with clinically meaningful improvements in proteinuria, with a 53.5% reduction from baseline in UPCR (n=5) at 24 weeks.
In addition, at 24 weeks, 4/5 (80%) had achieved remission, as defined as UPCR < 0.5 g/g and ≥50% reduction in UPCR from baseline with stable renal function (≤ 25% reduction in eGFR from baseline).
In IgAN, treatment with low-dose povetacicept was also associated with a >60% reduction in the key disease-related biomarker galactose-deficient IgA1 (Gd-IgA1), as well as stable renal function as assessed by estimated glomerular filtration rate (eGFR) (+7.1% from baseline at 24 weeks; n=5).
The first participant with primary membranous nephropathy (pMN), also treated with povetacicept 80 mg SC every four weeks, achieved an immunological remission, defined as a reduction in the highly disease-relevant biomarker anti-PLA2R1 to an undetectable level, from a baseline of 209 to < 2 RU/mL by 22 weeks.
Povetacicept has been well tolerated, with no reported administration-associated reactions, no instances of IgG < 3 g/L, and no severe infections.
A higher dose of povetacicept, 240 mg SC every four weeks, continued to enroll, with initial data expected in 1H 2024.
Price Action: ALPN shares are up 39.35% at $14.66 on the last check Thursday.
Read Next: SolarWinds Shares Jump Following Q3 Results and Optimistic Full-Year Forecasts
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
